Impact of olanzapine on cognitive functions in patients with schizophrenia during an observation period of six months

Psychiatria Danubina

Volumn 23, Issue SUPPL. 1, 2011, Pages

  Klasik, Adam ^a   Krysta, Krzysztof ^b   Krzystanek, Marek ^b   Skałacka, Katarzyna ^a  

^a UNIVERSITY OF OPOLE   (Poland)

^b MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Attention; Cognitive processes; Olanzapine; Reaction time; Schizophrenia

Indexed keywords

BENZODIAZEPINE; OLANZAPINE;

CLINICAL ARTICLE; CLINICAL OBSERVATION; COGNITION; CONFERENCE PAPER; DRUG EFFECT; HUMAN; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NEUROPSYCHOLOGICAL TEST; OUTCOME ASSESSMENT; RESPONSE TIME; SCHIZOPHRENIA; VIENNA TEST SYSTEM;

ANALYSIS OF VARIANCE; ANTIPSYCHOTIC AGENTS; ATTENTION; BENZODIAZEPINES; COGNITION; FOLLOW-UP STUDIES; HUMANS; NEUROPSYCHOLOGICAL TESTS; REACTION TIME; SCHIZOPHRENIA;

EID: 80052858504     PISSN: 03535053     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (23)

1. Bilder RM, Goldman RS, Robinson D, Reiter G, Bell L, Bates JA et al: Neuropsychology of first-episode schizophrenia: initial characterization and clinical correlates. Am J Psychiatry 2000; 157:549-59. (Pubitemid 30191193)
2. Forbes NF, Carrick LA, McIntosh AM & Lawrie SM: Working memory in schizophrenia: a meta-analysis. Psychol Med 2009; 39:889-905.
3. Goldman-Rakic PS: The physiological approach: functional architecture of working memory and disordered cognition in schizophrenia. Biol Psychiatry 1999; 46:650-61.
4. Good KP, Kiss I, Buiteman C, Woodley H, Rui Q, Whitehorn D & Kopala L: Improvement in cognitive functioning in patients with first-episode psychosis during treatment with quetiapine: an interim analysis. Br J Psychiatry Suppl 2002; 43:45-9.
5. Grootens KP, van Veelen NM, Sitskoorn MM, Sabbe BG, Peuskens J, Buitelaar JK et al.: Effects on cognitive functioning after olanzapine-ziprasidone crossover in recent-onset schizophrenia. Eur Neuropsychopharmacol 2010; 20:907-12.
6. Harvey PD, Bowie CR & Loebel A: Neuropsychological normalization with long-term atypical antipsychotic treatment: results of a six-month randomized, double-blind comparison of ziprasidone vs. olanzapine. J Neuropsychiatry Clin Neurosci 2006; 18:54-63. (Pubitemid 43277257)
7. Harvey PD, Green MF, McGurk SR & Meltzer HY: Changes in cognitive functioning with risperidone and olanzapine treatment: a large-scale, double-blind, randomized study. Psychopharmacology (Berl) 2003; 169:404-11. (Pubitemid 37255530)
8. Harvey PD: Cognitive Outcomes in the CATIE Schizophrenia Trial: Why do they seem different from previous results? Psychiatry (Edgmont) 2007; 4:20-3.
9. Javitt DC: Glutamatergic theories of schizophrenia. Isr J Psychiatry Relat Sci 2010; 47:4-16.
10. Kantrowitz JT & Javitt DC: N-methyl-d-aspartate (NMDA) receptor dysfunction or dysregulation: the final common pathway on the road to schizophrenia? Brain Res Bull 2010a; 83:108-21.
11. Kantrowitz JT & Javitt DC: Thinking glutamatergically: changing concepts of schizophrenia based upon changing neurochemical models. Clin Schizophr Relat Psychoses 2010b; 4:189-200.
12. Keefe RS, Seidman LJ, Christensen BK, Hamer RM, Sharma T, Sitskoorn MM et al: Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol. Am J Psychiatry 2004; 161:985-95. (Pubitemid 38735984)
13. Keefe RS, Young CA, Rock SL, Purdon SE, Gold JM & Breier A; HGGN Study Group: One-year double-blind study of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in schizophrenia. Schizophr Res 2006; 81:1-15.
14. Lindenmayer JP, Bernstein-Hyman R & Grochowski S. A new five factor model of schizophrenia. Psychiatr Q 1994; 65:299-322.
15. Ljubin T, Zakić Milas D, Mimica N, Folnegović-Smalc V & Makarić G: A preliminary study of the comparative effects of olanzapine and fluphenazine on cognition in schizophrenic patients. Hum Psychopharmacol 2000; 15:513-9.
16. McGurk SR, Lee MA, Jayathilake K & Meltzer HY. Cognitive effects of olanzapine treatment in schizophrenia. MedGenMed 2004; 6:27.
17. Meltzer HY & McGurk SR: The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bull 1999; 25:233-55. (Pubitemid 29272503)
18. Pardo JV, Pardo PJ, Humes SW & Posner M: Neurocognitive dysfunction in antidepressant-free, non-elderly patients with unipolar depression: Alerting and covert orienting of visuospatial attention. J Affect Disord 2006; 92:71-8.
19. Purdon SE, Jones BD, Stip E, Labelle A, Addington D, David SR, et al.: Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia. Arch Gen Psychiatry 2000; 57:249-58. (Pubitemid 30140434)
20. Rund BR, Sundet K, Asbjørnsen A, Egeland J, Landr? NI, Lund A et al: Neuropsychological test profiles in schizophrenia and non-psychotic depression. Acta Psychiatr Scand 2006; 113:350-9.
21. Schuhfried G: Wiener Testsystem. Vienna Reaction Unit, Basic Program, Development and production of scientific equipment. Mödling: Schuhfied GmbH, 1992.
22. Sharma T, Hughes C, Soni W & Kumari V: Longitudinal study of symptoms and cognitive function in chronic schizophrenia. Psychopharmacology (Berl) 2003; 169:398-403. (Pubitemid 37255529)
23. Stip E, Remington GJ, Dursun SM, Reiss JP, Rotstein E, MacEwan GW, et al. Canadian Switch Study Group: A Canadian multicenter trial assessing memory and executive Junctions in patients with schizophrenia spectrum disorders treated with olanzapine. J Clin Psychopharmacol 2003; 23:400-4. (Pubitemid 36951183)